Protocadherins play important roles in the regulation of cell adhesion and signaling transduction. Aberrant expression of protocadherins has been shown to be associated with multiple tumorigenesis. We previously identified PCDH17, encoding protocadherin 17, as a frequently methylated and downregulated tumor suppressor gene (TSG) in gastric and colorectal cancers. Here, we examined the abnormalities and functions of PCDH17 in breast cancer pathogenesis. We used PCR and immunohistochemistry to check its expression pattern in breast tumor cell lines and primary tumors. Methylation-specific PCR (MSP) was applied to examine its promoter methylation status in breast tumor cell lines and primary tumors. The biological functions of PCDH17 in breast tumor cells were assessed using in vitro and in vivo assays. We found that PCDH17 was frequently downregulated or silenced in 78% (7/9) of breast tumor cell lines, as well as 89% (32/36) of primary tumors. Downregulation of PCDH17 in breast cancer was mainly due to the methylation of its promoter. Ectopic expression of PCDH17 in breast tumor cells inhibited cell proliferation and mobility through arresting cell cycle and inducing apoptosis. In breast tumor cells, PCDH17 significantly suppressed the active β-catenin level and its downstream target gene expression. Thus, we found that PCDH17 functions as a tumor suppressor inhibiting Wnt/β-catenin signaling and metastasis in breast cancer but is frequently methylated in primary tumors which could be a potential biomarker.
INTRODUCTION
Breast cancer is the major cause of cancer-related morbidity and mortality in females worldwide [1] . Although many drugs and therapeutic regimens have been developed for the treatment of breast cancer, there is no cure for patients with systemic metastatic breast cancer. Diagnosis of breast cancer during its early stages correlates with increased overall survival rate. Therefore, females with high risk of developing breast cancer are encouraged to undergo mammography on an annual basis. However, tumors could evade detection by conventional physical examinations during their early stages.
Promoter methylation of tumor suppressor genes (TSGs) has been widely investigated and found to promote breast tumorigenesis. The expression of many TSGs, such as BRCA1, ERa and RASSF1A are downregulated in breast cancer, by promoter methylation [2] [3] [4] [5] . Our group Research Paper www.impactjournals.com/oncotarget also identified some TSGs methylation in breast cancer, including DACT1, ZNF545, PLCD1, UCHL1, DKK3, which contributes to tumor malignant progression [6] [7] [8] [9] [10] . Promoter methylation is the primary mechanism for transcriptional repression of TSGs, thus could serve as a biomarker for early detection of breast cancer [2, [11] [12] [13] [14] .
Expression profiling and epigenetic studies have been conducted to identify candidate TSGs. The PCDH17 gene, encoding the protocadherin 17 (PCDH17) protein, has been identified as a TSG [15] . PCDH17, located on chromosome 13q21.1, is frequently downregulated. Hypermethylation of its promoter has been found in esophageal, renal, and digestive carcinomas [15] [16] [17] . It is unclear whether PCDH17 acts as a TSG in breast cancer. Therefore, we investigated PCDH17 expression levels and the methylation status of its promoter in breast tumor cell lines and primary tissues, as well as its biological functions in breast tumorigenesis.
RESULTS

PCDH17 expression is downregulated in both breast tumor cell lines and primary breast tumors
We examined expression levels of PCDH17 in breast tumor cell lines, normal breast tissue samples, and breast tumor samples using semi-quantitative RT-PCR, quantitative real-time PCR (qPCR) and immunohistochemistry analysis.
PCDH17 expression was markedly repressed in seven of the nine breast tumor cell lines tested, and weakly expressed in BT549, YCC-B3 and Sk-BR-3 cell lines. In contrast, strong expression of PCDH17 was found in normal breast tissues ( Figure 1A ). The average mRNA expression level of PCDH17 in 18 breast tumor samples was significantly decreased compared with normal tissues (p < 0.05, Figure  2A , 2B). Immunohistochemistry results showed that protein expression levels of PCDH17 in breast tumor tissues were repressed in 89% (32/36) of cases, in comparison with those seen in normal tissues (p < 0.01, Figure 2C, 2D) . We failed to observe any correlation between PCDH17 expression levels and clinicopathological characteristics of breast cancer. These findings suggest that PCDH17 expression is downregulated in breast tumor cell lines and primary breast tumors.
Promoter methylation contributes to PCDH17 downregulation in breast tumor cell lines
We next determined whether promoter methylation is involved in PCDH17 downregulation in breast cancer. Typical CpG islands were found in the promoter regions and exon 1 of PCDH17 using CpG island analysis software (http://cpgislands.usc.edu/) (data not shown). We used methylation-specific PCR (MSP) to analyze PCDH17 promoter methylation status in nine breast tumor cell lines. Methylation of the PCDH17 promoter was observed in seven of the nine breast tumor cell lines, which was consistent with its low expression or absence ( Figure 1A ). To clarify whether PCDH17 silencing was a direct result of promoter methylation, we treated BT549, MB231, MCF7, T47D, and MB468 cell lines with Aza and TSA, and then performed MSP analysis. We observed that PCDH17 expression was rescued following the treatment with Aza and TSA, along with demethylation of the PCDH17 promoter, as demonstrated by MSP and bisulfite sequencing ( Figure 1B, 1C) . These results suggest that promoter methylation is directly responsible for PCDH17 downregulation in breast tumor cells.
We also investigated PCDH17 promoter methylation in breast tumor tissues. We observed that PCDH17 was methylated in 93.3% (97/104) of primary breast tumor tissues, and 25% (4/16) of normal breast tissues (Table 1 , Figure 3A , 3B). 14 pairs of primary breast tumor tissues and surgical margin tissues were also tested for PCDH17 expression and promoter methylation by qPCR and MSP respectively. All 14 tumors have lower PCDH17 mRNA expression compared with their paired surgical margin tissues ( Figure 3C ), while displaying a higher level of promoter methylation ( Figure 3D ). However, there was no correlation between PCDH17 promoter methylation and clinicopathological characteristics (data not shown).
PCDH17 inhibits cell proliferation in breast tumor cells
PCDH17 silencing via promoter methylation in breast cancer suggests that it might function as a TSG. To investigate the effects of PCDH17 on cell proliferation, we conducted colony formation assays. Ectopic expression of PCDH17 suppressed the colony formation abilities of breast tumor cells (MB231 and MCF7), with an approximate 50-60% reduction in colony numbers in comparison with cells transfected with control vectors (Figure 4A, 4B ). To explore whether PCDH17 affected cell cycle and apoptosis of breast tumor cells, flow cytometry analyses were performed. Cell cycle results showed that PCDH17-transfected cells were arrested more often in the G0/G1 phase than those transfected with the empty control vector (p < 0.01, Figure 4C , 4D), accompanied by a decrease in the number of PCDH17-expressing cells in the S and G2/M phases ( Figure 4C , 4D). Western blot further confirmed increased levels of p21 and p27 protein expression, and decreased levels of cyclin D1 and cyclin B1 protein expression in PCDH17-transfected cells ( Figure 6B ). Annexin V-FITC/PI staining results indicated that PCDH17 has a pro-apoptotic effect on breast tumor cells (p < 0.001, Figure 4E ).
PCDH17 suppresses epithelial-mesenchymal transition (EMT) and migration of breast tumor cells
We found that ectopic PCDH17 expression caused significant changes in cell morphology. Vector-transfected cells showed spindle-shaped morphology like fibroblasts, while a large proportion of PCDH17-transfected cells are elliptical shaped, suggesting that PCDH17 most likely reversed tumor cell EMT ( Figure 5A ). qPCR showed that expression of the epithelial marker E-cadherin was upregulated in PCDH17-expressing cells, while Vimentin and SNAIL were repressed, providing more evidence that PCDH17 represses EMT ( Figure 5E ). Western blot confirmed the changes of E-cadherin and Vimentin on the protein level ( Figure 5G ). Furthermore, immunofluorescence staining (IF) showed a significant co-expression of protocadherin 17 with E-cadherin, while Vimentin expression was depleted in PCDH17-transfected cells ( Figure 5F ). Transwell assay showed that the number of migrated cells was significantly reduced in cells with ectopic expression of PCDH17 than the control cells (p<0.01, Figure 5B , 5C). Furthermore, wound healing assay, at 30 h and 48 h, showed that PCDH17-expressing cells migrated along the edges of wounds at a much slower rate than those transfected with empty control vectors, indicating that PCDH17 inhibits cell migration ( Figure 5D ).
PCDH17 regulates Wnt/β-catenin signaling in breast tumor cells
The Wnt/β-catenin signaling pathway contributes to breast cancer proliferation and metastasis. Certain protocadherins are capable of directly binding to β-catenin and/or decreasing its activity. Therefore, it is possible that PCDH17 could be an antagonist of Wnt/β-catenin signaling in breast cancer. We found that protein expression of active β-catenin, but not total β-catenin, was reduced in PCDH17-transfected MB231 cells by immunofluorescence ( Figure 6A , 6C). Reduced expression of active β-catenin and its downstream target genes c-Myc and cyclin D1 was also observed in PCDH17-transfected tumor cells (MB468, MCF7 and MB231) by western blot ( Figure 6B ). This result was verified by qPCR detection of β-catenin, cyclin D1, and c-Myc mRNA expression in MB231 cells ( Figure 6D ). We also detected the expression of stemness markers using qPCR. Only CD44 expression was significantly inhibited by PCDH17 ( Figure 6E ). Western blot detection of CD44 corroborated with qPCR ( Figure 6F ).
PCDH17 suppresses proliferation of breast tumor cells in vivo
MB231 cells transfected with empty control vectors or PCDH17 were injected subcutaneously into nude mice to generate xenograft tumor models. These models were used to evaluate the tumor suppressive function of PCDH17 in vivo. The size and weight of tumors induced by PCDH17-expressing cells were significantly decreased compared with controls ( Figure 7A, 7B) . The effect of PCDH17 on tumor cell growth was also assessed by immunohistochemical staining. Expression level of Ki67 was reduced in tumors where PCDH17 was present ( Figure 7C, 7D) . Proliferation of the PCDH17-transfected xenografts was suppressed due to escalated apoptosis, as the levels of cleaved poly ADP-ribose polymerase (PARP) and cleaved caspase-3 are significantly higher than the control group ( Figure 7E ).
DISCUSSION
Protocadherins are a subfamily of the cadherin superfamily of proteins. However, little is known about their roles in cancers. Protocadherins are predominantly expressed during development of the nervous system, and their functions could be related to the differentiation of embryonic cells [18] [19] [20] . Repression of protocadherin expression might contribute to tumorigenesis. It was previously shown that expression levels of protocadherins, such as PCDH8, PCDH10, and PCDH20, were downregulated by promoter methylation in various carcinomas [21] [22] [23] , which were strongly associated with advanced cancer or poor outcome. Consistent with our findings, other members of the protocadherin family also obstruct tumor progression by antagonizing Wnt/β-catenin pathway in malignancies such as hepatocellular carcinoma and endometrial carcinoma [24, 25] . These studies suggest that protocadherins play crucial roles in the development of cancer. Hence, there is immense clinical value in investigating the expression and promoter methylation of protocadherin genes in breast cancer. We observed that PCDH17 were reduced in breast tumor cell lines and primary tumor samples. We found that PCDH17 expression was downregulated or silenced in all of the cell lines examined. MSP and bisulfite sequencing revealed that PCDH17 promoter methylation was partially responsible for its downregulation in breast tumor cells. The correlation between promoter methylation and downregulated expression was observed in most, but not all, of the cell lines. The methylation of PCDH17 promoter regions in BT549 and YCC-B3 cells showed a limited inhibiting effect on mRNA expression. In SK-BR-3 cell lines, PCDH17 expression was weak, yet, no methylation was observed in SK-BR-3 cell. These might be caused by the heterogeneity of tumor cells, and also suggest that other mechanisms such as histone deacetylation might be involved. Expression of PCDH17 was repressed in 89% (32/36) of breast tumor tissue samples, indicating that a loss of PCDH17 expression could lead to breast tumorigenesis. In addition, the PCDH17 promoter was frequently methylated in breast tumors. Thus, PCDH17 promoter methylation could be a potential biomarker for the diagnosis of breast cancer.
The biological functions of PCDH17 in breast cancer are unclear. The PCDH17 protein contains six cadherin repeats, an RGD motif in the extracellular domain, and highly conserved motifs (CM1, CM2) in the cytoplasmic domain [26] . Protocadherin 17 was detected during development of the nervous system in humans, and its dysfunction was linked to schizophrenia [26] . Little is known about the molecular mechanisms of PCDH17 during the development of breast cancer. During our investigation, we observed a significant change in the morphology of mesenchymal MB231 cells. The cells displayed epithelial traits after restoring PCDH17 expression. Thus, protocadherin 17 may be able to reverse EMT. IF and western blot results support this hypothesis as epithelial marker E-cadherin was upregulated and mesenchymal marker Vimentin was inhibited by PCDH17. PCDH20 was also able to suppress EMT by enhancing E-cadherin in nasopharyngeal carcinoma [27] , which suggests that the protocadherin family plays a regulatory role in the EMT process.
PCDH17 has been shown to have suppressive effects on the proliferation of tumor cells by inducing apoptosis and cell cycle arrest. We confirmed that ectopic expression of PCDH17 resulted in the arrest of cell cycle, and the induction of cell apoptosis in breast tumor cells. This occurred partially through the upregulated expression of p21 and p27, and reduced expression of cyclin D1 and cyclin B1. PCDH17 also suppressed β-catenin activity in breast tumor cells, although the molecular mechanism remains unknown and requires further investigation. In a recent study, Wnt/ β-catenin signaling was inhibited by PCDH20 through phosphorylation of GSK-3β in hepatocellular carcinoma [24] . It is possible that they share the same mechanism of suppressing tumor growth.
PCDH17 also inhibited the expression of c-Myc, another downstream target of β-catenin. This signaling pathway most likely also contributes to the tumorsuppressive effect of PCDH17, as c-Myc is an important oncogenic transcriptional factor [28] . We found that suppression of CD44 is involved in this process. CD44 is a receptor for hyaluronic acid and influences many characteristics of cancer cells, including stemness [29] . This implies that PCDH17 could possibly act as a suppressor of breast cancer stemness and plays a role in the initiation of the disease, which is worth looking into.
In summary, we found that PCDH17 expression is frequently repressed, or silenced, in breast tumor cell lines when its promoter is methylated. Expression of PCDH17 could be reactivated by pharmacological demethylation. Downregulation of PCDH17 and methylation of its promoter were common events in breast cancer. We further confirmed the suppression of PCDH17 on breast tumor cell proliferation and metastasis. Taken together, these results indicate that PCDH17 is a functional TSG in breast tumor pathogenesis.
MATERIALS AND METHODS
Cell lines and tumor samples
Breast cancer cell lines (MB231, MB468, MCF7, BT549, T47D, SK-BR-3, ZR-75-1, YCC-B1, YCC-B3) were used. Cell lines were maintained in RPMI 1640 (Gibco BRL, Karlsruhe, Germany) supplemented with 10% fetal bovine serum (FBS; Invitrogen, Carlsbad, CA, USA), 100 U/mL penicillin, and 100 U/mL streptomycin at 37°C/5% CO 2 [8, 30] . Samples of DNA and RNA were obtained from primary breast tumor tissues, paired margin tissues, and normal breast tissues. Fresh cancer tissues and adjacent normal tissues were obtained from patients who underwent primary surgery at the Surgery Department of the First Affiliated Hospital of Chongqing Medical University. Our study was approved by the Institutional Ethics Committees of the First Affiliated Hospital of Chongqing Medical University (Approval Notice 2010/2012(23)). Our experiments were undertaken with the understanding and written consent of each subject.
DNA and RNA extraction
Genomic DNA was extracted from cell lines and tissues using DNAzol Reagent (Invitrogen, Rockville, MD, USA) and the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturers' protocols. Total RNA was isolated from cell lines and tissues using TRI Reagent (Molecular Research Center, Cincinnati, OH, USA). The concentration of RNA samples was determined by spectrophotometry using a NanoDrop 2000 (Thermo Scientific, Wilmington, DE, USA). DNA and RNA integrity were determined by gel electrophoresis. Samples were stored at −80°C until required.
Immunohistochemical staining
Clinical tissue samples were fixed in 4% paraformaldehyde after surgical procedures. The samples were embedded in paraffin before cutting into 4 μm sections. The sections were dewaxed and rinsed in absolute xylene. The sections were then rehydrated through graded alcohol. Antigen retrieval was performed. To block endogenous peroxidase activity, the sections were incubated in 3% hydrogen peroxide and then washed with phosphate-buffered saline (PBS). Blocking was performed with 5% FBS-PBS solution for 15 min at room temperature. The sections were incubated at 4°C overnight with rabbit monoclonal antibody (PCDH17, 1: 100 dilution; Ki67 Ready-to-use). On the following day, the slides were washed with PBS and incubated with secondary antibody for 15 min at room temperature, followed by color development with Diaminobenzidine (DAB). The cell nuclei were counterstained with hematoxylin. Images were captured with a microscope.
DNA demethylation
Breast cancer cell lines were subjected to DNA demethylation treatments, as previously described [8] . Cell lines were treated with 10 mM 5-aza-2′-deoxycytidine (Aza) (Sigma-Aldrich, Steinheim, Germany) for 3 days, and then treated with 100 nM trichostatin A (TSA) (SigmaAldrich, Steinheim, Germany) for an additional 24 h.
Semi-quantitative PCR and quantitative PCR (qPCR) assays
For semi-quantitative PCR, the PCDH17 gene was amplified using Go-Taq (Promega) as previously described with GAPDH as a control [31] . Primers used were PCDH17-F: 5′-TGGAGGAGAGGAACGCCATG-3′ and PCDH17-R: 5′-AACAAACTGCTGCCTGCTGC-3′. Quantitative real-time PCR was carried out in the HT7500 system (Applied Biosystems, Foster City, CA, USA) using the SYBR® Green PCR Master Mix (Thermo Fisher Scientific, Hong Kong). The GAPDH gene, encoding glyceraldehyde 3-phosphate dehydrogenase, was selected as a reference gene for qPCR assays. Primers used in this study are listed in Table 2 .
DNA bisulfite treatment and methylation-specific PCR (MSP)
Bisulfite modifications of DNA and MSPs were performed as previously described [32, 33] . Bisulfite-treated DNA was amplified by MSP with primers PCDH17-m1 (5′-GATTATCGGGTGTCGTAGTTC-3′) and PCDH17-m2 (5′-CCCTAACGCAACGTACGCG-3′) for methylated samples, or PCDH17-u1 (5′-AGATTATTGGGTGTTG TAGTTT-3′)and PCDH17-u2 (5′-AACCCTAACACAA CATACACA-3′) for unmethylated samples. MSPs were conducted for 40 amplification cycles using AmpliTaqGold DNA Polymerase (Applied Biosystems), with annealing temperatures at 60 and 58°C for methylated and unmethylated samples, respectively. Methylated and unmethylated human DNA samples were used as positive and negative controls, respectively. Amplicons were analyzed following electrophoresis on 2% (w/v) agarose gels, which included 100 bp DNA markers (MBI Fermentas, Vilnius, Lithuania).
For BGS (bisulfite genomic sequencing), bisulfite-treated DNA was amplified using BGS primers ( Table 2 ). The PCR products were purified and cloned into pCR4-Topo vector (Invitrogen, Carlsbad, CA), with 8 to 12 colonies randomly chosen and sequenced.
Colony formation assays
MB231 and MCF7 cells were seeded in 6-well plates and transfected with an empty control vector, or a plasmid containing the full-length cDNA of PCDH17, using Lipofectamine™ 2000 (Invitrogen) according to the manufacturer's instructions. At 48 h post-transfection, cells were collected, re-plated, and selected for 2 weeks in the presence of 1.2 or 0.2 mg/ mL G418 for MB231 and MCF7 cells, respectively. Survived colonies were counted following staining with Giemsa's solution. www.impactjournals.com/oncotarget
Wound healing assays and transwell assays
Following stable transfection, the cells were cultured in 6-well plates until they were confluent. Cultures were wounded using sterile pipette tips, washed twice with PBS, and re-suspended in fresh culture medium. MB231 and MCF7 cultures were incubated at 37°C/5% CO 2 for 30 and 48 h, respectively. Cultures were then assessed at low power using a phase-contrast microscope (Nikon, Japan). Experiments were conducted in triplicate.
Cell migration was also assessed using transwell chambers (8-μm pore size, Corning, NY). MB231 cells stably expressing empty vectors or PCDH17 were washed twice in serum-free medium and plated onto transwell filter inserts in 24-well plates. The lower chambers contained 800 μL medium with 10% FBS. The cells were incubated at 37°C/5% CO2 for 24 h and fixed in 4% paraformaldehyde for 30 min, then stained with 100 ng/mL 4',6'-diamidino-2-phenylindole hydrochloride (DAPI) for 15 min. Nonmigratory cells in the upper chamber were removed with a cotton swab. Cells were photographed and counted under a microscope in five random fields.
Immunofluorescence staining
Cells were cultured on glass coverslips and transfected with PCDH17. 48 h after transfection, cells were fixed for 10 min in 4 % paraformaldehyde in PBS (pH 7.4), then permeabilized for 4 min in 0.1% Triton X-100 in PBS. Cells were blocked for 1h with 1% bovine serum albumin in PBS and then incubated with primary antibodies against PCDH17 (Sigma-Aldrich, HPA026817), E-cadherin (Abcam, Cambridge, MA), and Vimentin (Abcam, Cambridge, MA) overnight at 4°C. Nuclei were counter stained with DAPI. Images were captured using a fluorescence microscope (Leica DM IRB).
Analysis of cell cycle
To assess cell cycle status, MB231 and MCF7 cells were cultured in 6-well plates (2 × 10 5 cells/well) and incubated at 37°C/5% CO 2 . Cultures were transiently transfected with 4 μg of pcDNA3.1(+)-Flag-PCDH17 plasmid or empty control vectors using Lipofectamine™ 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's recommendations. After 48 h, cells were digested using 0.1% trypsin and centrifuged (900 rpm, 5 min). Cells were washed twice with PBS, fixed with icecold 70% ethanol for 1 h, and treated with 100 mL of 50 mg/L propidium iodide (PI) at 4°C for 30 min in the dark. Annexin V-FITC/PI staining was applied for apoptosis analysis. Data were analyzed using CellQuest™ Pro (BD Biosciences, San Jose, CA). 
Western blotting analysis
At 48 h post-transfection, cells were harvested and lysed with M-PER Mammalian Protein Extraction Reagent (Pierce, Cramlington, UK) containing a protease inhibitor cocktail (Sigma-Aldrich). Proteins in cell lysates (50 μg of total protein) were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and then transferred to polyvinylidene difluoride membranes (Bio-Rad, Hercules, CA, USA). We used primary antibodies against PCDH17 (Sigma-Aldrich), active β-catenin, total β-catenin, c-Myc, cyclin D1, cyclin B1, p27, p21 (Cell Signaling Technology, USA) and GAPDH (Southern Biotech, Birmingham, AL, USA). Protein bands were visualized using an enhanced chemiluminescence kit (Amersham Pharmacia Biotech, Piscataway, NJ, USA).
In vivo tumorigenicity
4-week-old female BALB/c nude mice (6 mice/ group) were injected subcutaneously with vector-or PCDH17-stably transfected MB231 cells (5×10 6 ). Tumor volume (mm3) was calculated using the following equation: volume = 0.5 × length × width^2. Before the length of the largest tumor reached 1cm, all mice were sacrificed and the tumors were removed and weighed. For immunohistochemical analyses, paraffinembedded sections were prepared from the xenografts. Proliferation score was calculated by counting the number of Ki67-positive cells in 100 tumor cells in 10 randomly selected fields on one slide under x 400 magnification. All procedures were approved by the Animal Ethics Committee of the Experimental Animal Center of the Chongqing Medical University, Chongqing, China.
Statistical analysis
Statistical analyses were performed with SPSS version 16 (SPSS Inc., Chicago, IL, USA). Student's t-test, χ 2 tests, and Fisher's exact test were used to compare methylation status and clinicopathological parameters. For all tests, a p-value less than 0.05 was considered statistically significant.
